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Abstract: Carnosine is an endogenous dipeptide composed ofβ-alanine and L-histidine. This naturally
occurring molecule is present at high concentrations in several mammalian excitable tissues such as
muscles and brain, while it can be found at low concentrations in a few invertebrates. Carnosine
has been shown to be involved in different cellular defense mechanisms including the inhibition of
protein cross-linking, reactive oxygen and nitrogen species detoxification as well as the counteraction
of inflammation. As a part of the immune response, macrophages are the primary cell type that
is activated. These cells play a crucial role in many diseases associated with oxidative stress and
inflammation, including atherosclerosis, diabetes, and neurodegenerative diseases. In the present
study, carnosine was first tested for its ability to counteract oxidative stress. In our experimental
model, represented by RAW 264.7 macrophages challenged with phorbol 12-myristate 13-acetate
(PMA) and superoxide dismutase (SOD) inhibitors, carnosine was able to decrease the intracellular
concentration of superoxide anions (O2−•) as well as the expression of Nox1 and Nox2 enzyme genes.
This carnosine antioxidant activity was accompanied by the attenuation of the PMA-induced Akt
phosphorylation, the down-regulation of TNF-α and IL-6 mRNAs, and the up-regulation of the
expression of the anti-inflammatory mediators IL-4, IL-10, and TGF-β1. Additionally, when carnosine
was used at the highest dose (20 mM), there was a generalized amelioration of the macrophage energy
state, evaluated through the increase both in the total nucleoside triphosphate concentrations and
the sum of the pool of intracellular nicotinic coenzymes. Finally, carnosine was able to decrease the
oxidized (NADP+)/reduced (NADPH) ratio of nicotinamide adenine dinucleotide phosphate in a
concentration dependent manner, indicating a strong inhibitory effect of this molecule towards the
main source of reactive oxygen species in macrophages. Our data suggest a multimodal mechanism
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of action of carnosine underlying its beneficial effects on macrophage cells under oxidative stress and
inflammation conditions.
Keywords: carnosine; macrophages; superoxide; oxidative stress; inflammation; antioxidants
1. Introduction
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are both part of natural
aerobic cell metabolism and are involved in the pathophysiology of different diseases [1,2]. Under
physiological conditions, the controlled production of ROS and RNS as well as the activity of the
cell antioxidant machinery are well-balanced [3], otherwise a well-known phenomenon named
“oxidative/nitrosative stress” will occur [4,5]. ROS, in most healthy cells, are formed as superoxide
anions (O2−•) by mitochondria, that generates O2−• during the tetravalent reduction of molecular
oxygen to water catalyzed by the electron transport chain and connected to adenosine triphosphate
(ATP) production [2,6–8]. Spontaneous O2−• dismutation is remarkably accelerated by superoxide
dismutase (SOD) activity, that leads to the formation of hydrogen peroxide and diatomic oxygen [9].
At physiological levels, O2−• is implicated in several functions such as the messenger of endothelial
function [10] and in the phosphorylation and activation of numerous protein kinases [11]. When
O2−• is overproduced and exceeds cell antioxidant defences, it can either generate secondary, more
dangerous ROS, or can easily react with nitric oxide (NO) to form the so-called “deadly cocktail”, as
defined by Estévez and Jordán [12]. Oxidative/nitrosative stress leads to the production of ROS and
RNS, including hydroxyl radicals and peroxynitrite, which are able to damage fatty acids, proteins,
DNA, carbohydrates, and mitochondria [12]. The reaction between O2−• and NO is faster than the
detoxification reaction catalyzed by SOD [13]. ROS and RNS are widely recognized as important
stress mediators of pro-inflammatory conditions, thus connecting oxidative stress and inflammation
phenomena [14].
When inflammation processes take place, inducible nitric oxide synthase (iNOS), responsible
for NO production [15], as well as NADPH oxidase (Nox), responsible for O2−• production [16],
are overexpressed in immune cells such as macrophages and microglia [17,18]. Different types
of cells are involved in the immune response, among others macrophages are those primarily
activated [19,20]. Macrophages can be classified in two different and functionally distinct
sub-populations: pro-inflammatory or classically-activated macrophages (M1) and anti-inflammatory
or alternatively activated macrophages (M2) [21]. While the M1 sub-population is associated with a
high production of pro-inflammatory cytokines (e.g., IL-1β, IL-6, TNF-α, and IL-1), ROS, and RNS, the
M2 sub-population produces anti-inflammatory cytokines (e.g., IL-4, IL-10, IL-13, and TGF-β1) [22].
Both peripheral macrophages and microglia, the resident macrophages of the brain, play a pivotal role
in several diseases characterized by both oxidative stress and inflammation [23,24].
Carnosine is a natural dipeptide (β-alanyl-L-histidine) discovered more than 100 years ago [25].
This molecule and its related compounds such as anserine (L-alanyl-1-methyl-L-histidine) and
homocarnosine (γ-amino-butyryl-L-histidine) are widely distributed in mammalian tissues [26]
and in a few number of invertebrates [27,28]. Carnosine is synthesized starting from β-alanine
and L-histidine via the activity of the enzyme carnosine synthetase 1, through an ATP-consuming
process [29,30]. Although carnosine is mainly found in muscles [31], where it can reach a concentration
close to 20 mM [32], its levels in the brain may also be considered reasonably high, ranging from 0.7
to 2.0 mM [33]. There are different in vivo studies in the literature showing the ability of carnosine
to protect against pathologies characterized by oxidative stress and/or inflammation. In the study
carried out by Zhang et al., employing a neonatal rat model, carnosine was able to protect against
hypoxia-ischemia brain damage [34]; Albrecht et al. demonstrated that carnosine treatment improves
glucose metabolism, albuminuria, and pathology in BTBR ob/ob mice [35]; very recently, Bermúdez
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and colleagues carried out an in vivo study in which intranasal carnosine administration attenuated
transcriptomic alterations and improved mitochondrial function in the Thy1-aSyn mouse model of
Parkinson’s disease (PD) [36]; lastly, carnosine rescued cognitive deficits and decreased expression
of the receptor for advanced glycation end products in blood vessels and microglial activation in a
transgenic mouse model of Alzheimer disease (AD) fed with a high fat diet [37]. Most of carnosine
protective activities are attributable to its antioxidant and anti-inflammatory properties [38]. The
interaction of carnosine with specific receptors localized on the cell membrane has been shown to
modulate macrophage function [39] by increasing their phagocytotic activity [40]. The ability of this
dipeptide to modulate NO production and macrophages polarization has also been proved [41,42].
Very recently, carnosine has been shown to decrease both oxidative stress and inflammation in an
in vitro model of amyloid-induced inflammation [43].
In the present study, we first investigated the production of O2−• induced by phorbol 12-myristate
13-acetate (PMA) and SOD inhibitors, in the absence or in the presence of increasing concentrations of
carnosine and anserine, in RAW 264.7 cells, representing an established in vitro experimental model
for studying oxidative stress, with particular reference to O2−• production [1,44–47]. Additionally, in
order to understand the molecular mechanisms underlying the ability of carnosine in counteracting
O2−• production, we studied the variation of parameters representative of cellular energy metabolism,
the expression of oxidative stress-related enzymes, and the expression of pro- and anti-inflammatory
cytokines in RAW 264.7 cells challenged with PMA and SOD inhibitors in the absence or in the
presence of carnosine. Lastly, relying on the fact that Akt protein is overactivated in macrophages
under pro-oxidative and pro-inflammatory conditions [48], we also evaluated the effect of carnosine
on the PMA-induced activation of Akt in RAW 264.7 macrophages.
2. Materials and Methods
2.1. Materials and Reagents
RAW 264.7 cells (ATCC® TIB-71™), Dulbecco’s Modified Eagle Medium (DMEM), fetal
bovine serum (FBS), and penicillin/streptomycin antibiotic solution were purchased from American
Type Culture Collection (ATCC, Manassas, VA, USA). Ultrapure standards for high-performance
liquid chromatography (HPLC), tetrabutylammonium hydroxide, L-carnosine, L-Anserine nitrate
salt, anhydrous dimethyl sulfoxide (DMSO), potassium chloride, sodium dodecyl sulfate (SDS),
phosphate-buffered saline (PBS), trypan blue solution, 2-methoxyestradiol (2-ME), cocktail of protease
inhibitors, serine/threonine phosphatase inhibitors, tyrosine protein phosphatases inhibitors, RIPA
buffer, bovine serum albumin, Bradford reagent, sodium diethyldithiocarbamate trihydrate (DDC),
and PMA were all supplied by Sigma-Aldrich (St. Louis, MO, USA). Centrifuge tubes equipped with
3 kDa molecular weight cut-off filters and water, methanol, far-UV acetonitrile, and chloroform (all
HPLC-grade) were supplied by VWR International (West Chester, PA, USA). MitoSOX Red probe
was purchased from Life Technologies (Carlsbad, CA, USA). C-Chip disposable hemocytometer was
purchased from Bulldog Bio, Inc. (Portsmouth, NH, USA). SuperScript III First-Strand Synthesis
SuperMix, TE buffer, 25 and 75 mL polystyrene culture flasks, 60 × 15 mm polystyrene Petri dishes,
phenol red-free RPMI-1640 medium, boric acid, sodium hydroxide, acetone, 2-propanol, ethanol (95%),
PierceTM BCA Protein Assay Kit, and Ne-PER Nuclear and Cytoplasmic Extraction Reagents were
obtained from Thermo Fisher Scientific Inc. (Pittsburgh, PA, USA). QuantiTect SYBR Green PCR Kits,
RNeasy Mini Kit, and QuantiTect Primer Assays, were purchased from Qiagen (Hilden, Germany).
Anti-GAPDH primary antibody was obtained from Millipore (Burlington, MA, USA); anti-nuclear
factor erythroid 2-related factor 2 (Nrf2), anti-Akt, and anti-p(ser473)Akt primary antibodies were
all obtained from Cell Signaling Technology Inc. (Danvers, MA, USA); anti-heme oxygenase 1
(HO-1) and anti-Histone H3 primary antibodies were purchased from Abcam (Cambridge, UK).
Secondary goat anti-rabbit labeled with IRDye 680 and goat anti-mouse labeled with IRDye 800 were
purchased from Li-COR Biosciences (Lincoln, NE, USA). 384-well plates were obtained by Roche
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Molecular Systems Inc. (Pleasanton, CA, USA). Eppendorf LoBind 1.5 mL Microcentrifuge Tubes PCR
Clean as well as PCR tubes were both obtained from Eppendorf (Hamburg, Germany). Sylgard 184
polydimethylsiloxane (PDMS) prepolymer and curing agent were obtained from Ellsworth Adhesives
(Germantown, WI, USA).
2.2. Cell Culture and Preparation
RAW 264.7 macrophages were cultured in DMEM plus supplements and maintained in polystyrene
culture flasks as previously described in detail [1]. Cells were passaged every 2 to 3 days depending
on the cell confluence to avoid overgrowth. On the day of the experiment, cells were harvested, 100 µL
of the cell suspension was used for cell counting (C-Chip disposable hemocytometer), and plated in
polystyrene culture flasks or Petri dishes at the appropriate density.
2.3. Superoxide Anion Levels Determination Using Microchip Electrophoresis with Laser-Induced Fluorescence
(ME-LIF) and MitoSOX Red Probe
MitoSOX Red (5 mM), DDC (100 mM), 2-ME (16.5 mM), and PMA (1 mg/mL) stock solutions
were prepared as previously described [47]. Macrophages, plated at the density of 3 × 106 cells/flask
and ready for the treatment, were incubated for 1 h with the two well-known SOD inhibitors, the
cytosolic DDC (1 mM final concentration) and the mitochondrial 2-ME (50 µM final concentration), in
presence of the MitoSOX Red probe (10 µM final concentration). Cells were then subjected to an acute
(30 or 60 min) stimulation with PMA (1 µg/mL) to increase O2−• production. To investigate the effects
of carnosine or its methylated analogue anserine on O2−• production, cells were pre-incubated for
24 h with increasing carnosine or anserine concentrations (5, 10, or 20 mM), before PMA stimulation.
During the incubation of the macrophages with MitoSOX Red, the flasks were always covered with
aluminium foil to minimize any photobleaching of the probe. Untreated cells from the same population
were used as a control. Cells were then harvested, counted, centrifuged, and the obtained cell pellet
was prepared and analyzed by ME-LIF as recently described [43].
Supplementary Figure S1 depicts the experimental procedure to measure O2−• production in
RAW 264.7 macrophages.
2.4. HPLC Analysis of Metabolites
Macrophage cells, plated at the density of 4.5 × 106 cells/Petri dish and stimulated as described
in Section 2.3, were deproteinized according to the organic solvent deproteinization, suitable to
measure acid labile and easily oxidizable compounds described in detail elsewhere [49]. The analytes
of interest were separated and quantified by ion-pairing HPLC method as previously described
in detail [50,51]. Identification and measurement of the different compounds in chromatographic
runs of cell extracts were performed by comparing retention times, absorption spectra, and area of
the peaks of chromatographic runs of mixtures containing known concentrations of true ultrapure
standard mixtures.
2.5. Gene Expression Analysis by Quantitative Real-Time PCR (qRT-PCR)
The concentration of total RNA recovered from 4.5 × 106 cells (previously seeded in Petri dishes)
by using RNeasy Mini Kit was determined by measuring the absorbance at 260 nm with a NanoDrop®
ND-1000 (Thermo Fisher Scientific, Waltham, MA, USA). The reverse transcription of 100 ng of total
RNA (for each sample) was accomplished by using the SuperScript III First-Strand Synthesis SuperMix
kit, while the quantification of each cDNA sample loaded in a 384-well plate was achieved by using a
LightCycler® 480 System (Roche Molecular Systems, Inc., Pleasanton, CA, USA). The list containing
the information of each primer used for this study is reported in Table 1.
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Table 1. The list of primers used for quantitative real-time PCR (qRT-PCR).
Official Name #
Official
Symbol
Alternative
Titles/Symbols
Detected
Transcript
Amplicon
Length Cat. No.
†
nitric oxide synthase
2, inducible Nos2
iNOS; Nos-2; Nos2a;
i-NOS; NOS-II;
MAC-NOS
NM_010927 118 bp QT00100275
NADPH oxidase 1 Nox1
MOX1; NOH1; NOH-1;
NOX1a; Nox-1; GP91-2;
NOX1alpha
NM_172203
XM_006528515 180 bp QT00140091
cytochrome b-245,
beta polypeptide Cybb
Cgd; Cyd; Nox2; C88302;
gp91-1; gp91phox;
CGD91-phox
NM_007807
XM_006527565 146 bp QT00139797
interleukin 1 beta Il1b Il-1b; IL-1beta; IL-1β NM_008361XM_006498795
150 bp
682 bp QT01048355
tumor necrosis factor Tnf
DIF; Tnfa; TNF-a;
TNFSF2; Tnlg1f; Tnfsf1a;
TNFalpha; TNF-alpha;
TNF-α
NM_013693
NM_001278601
112 bp
112 bp QT00104006
interleukin 6 Il6 Il-6 NM_031168 128 bp QT00098875
interleukin 4 Il4 Il-4; BSF-1 NM_021283 132 bp QT02418311
interleukin 10 Il10 CSIF; Il-10 NM_010548 103 bp QT00106169
transforming growth
factor, beta 1 Tgfb1
Tgfb; Tgfb-1; TGFbeta1;
TGF-beta1 NM_011577 145 bp QT00145250
glyceraldehyde-3-
phosphate
dehydrogenase
Gapdh Gapd
NM_008084
XM_001003314
XM_990238
NM_001289726
144 bp QT01658692
# [52]; † [53].
The protocol employed for sample amplification, fluorescence data collection, and sample
quantification is the same as previously described by us [43].
2.6. Western Blot Analysis
Western blot analyses were performed as previously described [54] on macrophages harvested at
4 ◦C in RIPA buffer in the presence of a cocktail of protease inhibitors, serine/threonine phosphatase
inhibitors, and tyrosine protein phosphatases inhibitors. After a sonication step, each lysate
was subjected to centrifugation and supernatant collection. The protein concentrations were
determined by Bradford reagent and by measuring the absorbance at 595 nm with a Varioskan® Flash
spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). A standard curve was made by
using bovine serum albumin. After blocking, membranes were incubated with the selected primary
antibodies (1:2000 for GAPDH; 1:500 for all other primary antibodies) overnight at 4 ◦C. After 3 washing
steps, membranes were incubated at room temperature, 60 min, with secondary goat anti-rabbit labeled
with IRDye 680 and goat anti-mouse labeled with IRDye 800 (1:15000 for both of them).
The nuclear translocation of Nrf2 in macrophages under all our experimental conditions was
measured by employing Ne-PER Nuclear and Cytoplasmic Extraction Reagents following the
manufacturer’s specification. Briefly, after centrifugation at 500× g for 3 min, the cellular pellet
was re-suspended in ice-cold CER I, vortexed, and incubated on ice. Next, the suspension was added
of ice-cold CER II and centrifuged in order to obtain supernatant cytoplasmic extract. The residual
pellet (nuclear fraction) was suspended in ice-cold NER, incubated on ice, and vortexed several times.
Lastly, the samples were centrifuged to obtain supernatant nuclear extract. After protein concentration
determination by using PierceTM BCA Protein Assay Kit, nuclear samples were analyzed as described
in the case of total protein extracts (Akt, pAkt, Nrf2, and HO-1). The dilution of Histone H3, used to
normalize the densitometric values of nuclear Nrf2 [55], was 1:30000.
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Hybridization signals were detected with the Odyssey Infrared Imaging System (LI-COR
Biosciences, Lincoln, NE, USA). Western blot data were quantified by densitometric analysis (Image J
software) of the hybridization signals.
2.7. Statistical Analysis
Graphpad prism (Graphpad software, San Diego, CA, USA) was the software selected to perform
the statistical analysis. Normal data distribution was tested using the Jarque–Bera test, before
performing the comparison within groups using the one-way analysis of variance (ANOVA) and the
Tukey test for multiple comparisons, as the post hoc test. Only two-tailed p-values less than 0.05 were
considered statistically significant.
3. Results
3.1. Carnosine Effects on PMA-Induced O2−• Production in Cultured Macrophages
Before monitoring the effects of carnosine or its methylated analogue anserine (5, 10, or 20 mM,
indicated in each figure as C5, C10, C20, or A5, A10, A20, respectively), we first investigated the
effects of acute stimulations of RAW 264.7 macrophages with 1 µg/mL PMA for 30 or 60 min on
O2−• production.
Figure 1A clearly shows the time-dependent increase in O2−• production induced by acute
stimulation with PMA. The shorter stimulation time (30 min) lead to a ~2.7-fold increase in O2−•
production compared to control (untreated) cells, while cells stimulated for the longer time (60 min)
had a further remarkable increase in O2−• production compared to both 30-min stimulation (~3.1-fold
increase, p < 0.01) and controls (~8.3-fold increase, p < 0.001).
Once the optimal cell stimulation protocol was established (60 min stimulation with 1 µg/mL
PMA), the effects of increasing carnosine and anserine (5, 10, or 20 mM) on intracellular O2−• levels
in stimulated macrophages were tested. Carnosine decreased O2−• production in PMA-stimulated
macrophages in a concentration-dependent manner (Figure 1B). Unlike 5 mM carnosine (−13% in
O2−• production, not significant), the pre-treatment with 10 mM (−30%, p < 0.001 vs. PMA; −17%,
p < 0.05 vs. PMA + C5) or 20 mM carnosine (−62%, p < 0.001 vs. PMA; −49%, p < 0.001 vs. PMA
+ C5; −32%, p < 0.01 vs. PMA + C10) led to significant decrease of intracellular O2−•. To evaluate
the impact of the freedom of the imidazole ring on the decrease of O2−• levels we have replicated
the experiment using anserine instead of carnosine. As observed for carnosine, the pre-treatment
with anserine decreased O2−• production in PMA-stimulated RAW 264.7 macrophages (Figure 1C).
The pre-treatment with 5 mM anserine did not affect the O2−• levels (−8%, not significative), while
both 10 mM (−24%, p < 0.05 vs. PMA) and 20 mM (−39%, p < 0.001 vs. PMA; −31%, p < 0.01 vs.
PMA + A5) significantly decreased O2−• levels. It is however worth underlining that each anserine
concentration tested was less effective than the corresponding concentration of carnosine. In particular,
20 mM carnosine caused 1.6 times stronger decrease in O2−• levels (−62%) compared to the same
concentration of its methylated analogue anserine (−39%, p < 0.01 compared to 20 mM carnosine).
3.2. Influence of Carnosine on Energy Metabolism of Cultured Macrophages
In Figure 2, the results show the effects of PMA and SOD inhibitors in absence or presence of
increasing concentrations of carnosine (5, 10, or 20 mM) on energy metabolites concentrations (ATP,
GTP, UTP, and CTP) of RAW 264.7 macrophages.
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Figure 1. Detection of intracellular concentrations of O2−• (a cted by microchip electrophoresis with
laser-induced fluorescence (ME-LIF)) in resting (control) macrophages and in macrophages stimulated with
phorbol 12-myristate 13-acetate (PMA) and superoxide dismutase (SOD) inhibitors, in absence or presence of
increasing concentrations (5, 10, or 20) of carnosine or anserine. (A) Change in O2−• production (expressed as
Average peak area/Cell) i macrophages subjected to two di ferent acute stimulatio s with PMA. (B,C) show
the ability of carnosine and anserine in decreasing the intracellular concentrations of O2−• PMA-induced,
respectively. The O2−• levels are expressed as the percent variation with respect to the PMA-stimulated cells.
Values are means ± SD of three to five independent experiments. *** p < 0.001 vs. CTRL; θ p < 0.05 vs. PMA
30 min; # p < 0.05 vs. PMA; ### p < 0.001 vs. PMA; φ p < 0.05 vs. PMA + C5; φφ p < 0.01 vs. PMA + C10;
φφφ p < 0.001 vs. PMA + C5;ωω p < 0.01 vs. PMA + A5.
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Figure 2. Changes in nucleoside triphosphate concentrations (ATP, GTP, UTP, and CTP), expressed
as nmol/million cells, in re ti g (control) macrophages and i crophages stimulated with PMA and
SOD inhibitors, in absence or presence of increasing concentrations (5, 10, or 20) of carnosine. Values are
means ± SD of four independent experiments. ** p < 0.01 vs. CTRL; ## p < 0.01 vs. PMA; ### p < 0.001
vs. PMA; φ p < 0.05 vs. PMA + C5 and PMA + C10; φφ p < 0.01 vs. PMA + C5 and PMA + C10.
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The short incubation time with PMA did not cause changes in any of these compounds. Similarly,
5 or 10 mM carnosine had no effects on the nucleoside triphosphates considered. Interestingly, 24 h
incubation with 20 mM carnosine before PMA challenge induced a significant increase in both ATP
(3.10 ± 0.32 nmol/106 cells, p < 0.01 vs. CTRL; p < 0.001 vs. PMA; p < 0.01 vs. PMA + C5 or C10)
and GTP (0.89 ± 0.29 nmol/106 cells, p < 0.01 vs. CTRL; p < 0.01 vs. PMA; p < 0.05 vs. PMA + C5 or
C10), while no effect was observed for UTP (1.33 ± 0.25 nmol/106 cells) and CTP (0.42 ± 0.11 nmol/106
cells). The total amount of nucleoside triphosphates (ATP + GTP + UTP + CTP) was 3.89 nmol/106
cells in control (untreated) cells and increased up to 5.76 nmol/106 cells (+47.9%) in PMA + 20 mM
carnosine-treated cells. Overall these data show a reinforcement of the cellular phosphorylating
capacity following the addition of 20 mM carnosine to macrophages before PMA challenge.
In the same experimental conditions, we evaluated the levels of intracellular nicotinic coenzymes
(NAD+ + NADH and NADP+ + NADPH) (Figure 3A).
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Figure 3. Consequences of th different c ll treatments on (A) sum (NAD+ + NADH and NADP+ +
NADPH) and (B) the ratio (NAD+/ ADH and NADP+/NA P ) of intracellular nicotinic coenzymes in
resting (control) macrophages and in macrophages stimulated with PMA and SOD inhibitors, in absence or
presence of increasing concentrations (5, 10, or 20) of carnosine. The sum of intracellular nicotinic coenzymes
is expressed as n ol/million cell . Values are means ± SD of four independent experiments. * p < 0.05 vs.
CTRL; ** p < 0.01 vs. CTRL; *** p < 0.001 vs. CTRL; # p < 0.05 vs. PMA; ## p < 0.01 vs. PMA; ### p < 0.001 vs.
PMA; φ p < 0.05 vs. PMA + C5 and PMA + C10; φφφ p < 0.001 vs. PMA + C5.
The sum of NAD+ + NADH, as well as that of NADP+ + NADPH, were not significantly affected
at any experimental conditions excepted for the PMA + C20 treatment. Indeed, significant increases
in both NAD+ + NADH (0.82 ± 0.16 nmol/106 cells, p < 0.01 vs. CTRL; p < 0.01 vs. PMA; p < 0.05
vs. PMA + C5 or C10) and NADP+ + NADPH (0.51 ± 0.01 nmol/106 cells, p < 0.05 vs. all other
treatments) were observed when using PMA C20 treatment, indicating a better coenzymatic set
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for oxido-reductive reactions. The apparent lack of effects of PMA was vice versa manifested when
considering the NAD+/NADH and NADP+/NADPH ratio (Figure 3B). PMA caused a 1.65-folds
decrease of NAD+/NADH (p < 0.05 vs. CTRL) that did not ameliorate with 5 mM carnosine. Differently,
10 mM carnosine normalized this ratio (not significant vs. CTRL; p < 0.01 vs. PMA) and 20 mM
carnosine caused a further increase up to values 1.45- and 2.40-folds higher than control and PMA,
respectively (p < 0.05 vs. CTRL; p < 0.001 vs. PMA; p < 0.001 vs. PMA + C5). A different trend was
observed when considering the NADP+/NADPH ratio; a 2.81-folds increase was measured for cells
treated with PMA and SOD inhibitors only (p < 0.001 vs. CTRL). A dose-response effect was noticed
for carnosine treatment, which, at 10 and 20 mM concentrations, normalized the ratio of these nicotinic
coenzymes (not significant vs. CTRL; p < 0.01 vs. PMA).
3.3. Carnosine Effects on PMA-Induced Inflammatory Response of Cultured Macrophages
Since the treatment of RAW 264.7 macrophages with carnosine decreased the PMA-induced
O2−• production (Figure 1B), we assessed the ability of carnosine to modulate the expression of Nox1
and Nox2 as well as that of iNOS enzyme and the genes responsible for the transcription of pro-
(TNF-α, IL-6, and IL-1β) and anti-inflammatory (TGF-β1, IL-4, and IL-10) cytokines in PMA-stimulated
macrophages. As expected, the expression level of Nox1 (+2.05-folds, p < 0.01 vs. CTRL) and Nox2
(+3.74-folds, p < 0.001 vs. CTRL) mRNAs was significantly increased following PMA treatment
(Figure 4A,B).Antioxidants 2019; FOR PEER REVIEW 10 of 20 
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Figure 4. Measurement of (A) Nox1, (B) Nox2, an ( ) iNOS mRNA xpression levels (quantitative
real-time PCR (qRT-PCR)) in resti g (control) macrophages and in ma r hage stimulated with PMA
and SOD inhibitors, in absence or presence of increasing concentrations (5, 10, or 20) of carnosine. The
abundance of each mRNA of interest was expressed relative to the abundance of GAPDH-mRNA, as an
internal control. As a negative control, a reaction in absence of c NA (no template control, NTC) was
performed. Values are means ± SD of three to se en independent experiments. ** p < 0.01 vs. CTRL; ***
p < 0.001 vs. CTRL; # p < 0.05 vs. PMA; ## p < 0.01 vs. PMA.
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Among the three carnosine concentrations used in our study, the highest concentration (20 mM)
was able to significantly decrease PMA-induced Nox1 activation (p < 0.05 vs. PMA), restoring values
not significantly different from those determined in controls. Both 10 and 20 mM carnosine effectively
decreased PMA-induced overexpression of Nox2 (p < 0.01 vs. PMA for both of them). The treatment
of RAW 264.7 macrophages with PMA, in presence or absence of increasing concentration of carnosine
did not significantly affect mRNA iNOS expression (Figure 4C).
Figure 5 shows the expression of genes related to the production of pro- (A–C) and anti-inflammatory
(D–F) cytokines in resting (control) RAW 264.7 macrophages and in macrophages stimulated with PMA and
SOD inhibitors, in absence or presence of increasing concentrations (5, 10, or 20) of carnosine.Antioxidants 2019; FOR PEER REVIEW 11 of 20 
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Figure 5. Measurem nt of (A) TNF-α, (B) IL-6, -1β, (D) TGF-β1, (E) IL-4, and (F) IL-10mRNA
expression levels (qRT-PCR) in resting (control) phages and in macrophages stimulated with
PMA and SOD inhibitors, in absence or presence of increasing concentrations (5, 10, or 20) of carnosine.
GAPDH-mRNA and NTC reactions were used as internal and negative controls, respectively, as
described in Figure 4. Values are means ± SD of three to seven independent experiments. * p < 0.05
vs. CTRL; ** p < 0.01 vs. CTRL; *** p < 0.001 vs. CTRL; # p < 0.05 vs. PMA; ## p < 0.01 vs. PMA;
### p < 0.001 vs. PMA; φ p < 0.05 vs. PMA + C5.
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Compared to control cells (Figure 5A–C), PMA treatment significantly increased the expression
levels of TNF-α (+3.36-folds, p < 0.05), IL-6 (+7.51-folds, p < 0.001), and IL-1β (+29.56-folds, p < 0.001).
Carnosine decreased TNF-α levels in a concentration-dependent manner (p < 0.001 vs. PMA for all
carnosine concentrations) up to values equaling those found in controls, when carnosine was used at
10 or 20 mM. A similar trend was observed in the case of IL-6 (p < 0.01 vs. PMA for PMA + C5 and
p < 0.001 vs. PMA for PMA + C10 or C20), although IL-6 expression was higher than control even
in presence of 20 mM carnosine. Unlike TNF-α and IL-6, carnosine treatment did not significantly
decrease the remarkable increased in IL-1β mRNA expression induced by PMA (p < 0.001 vs. CTRL).
Significant decrease in the expression levels of TGF-β1 was recorded after the challenge of macrophages
with PMA (−0.43-folds, p < 0.05 vs. CTRL)) (Figure 5D). Compared to control cells, PMA stimulation
did not affect the production of IL-4 and IL-10 (Figure 5E–F). Each of the three carnosine treatments (5,
10, and 20 mM) was able to restore TGF-β1 expression (Figure 5D), whilst only the 20 mM concentration
(Figure 5E) significantly increased IL-4 expression (p < 0.01 vs CTRL; p < 0.01 vs. PMA; p < 0.05 vs.
PMA + C5). It is also worth underlining that 10 and 20 mM carnosine significantly increased IL-10
expression (Figure 5F) notwithstanding the stimulation with PMA (p < 0.01 vs. PMA or vs. CTRL).
3.4. Carnosine Effects on PMA-Induced Akt Phosphorylation in Cultured Macrophages
To address whether the ability to decrease oxidative stress and inflammation was also connected
to other beneficial molecular phenomena, the effect of carnosine pre-treatment on Akt phosphorylation,
Nrf2, and HO-1 was studied in PMA-stimulated macrophages. As showed in Figure 6, the stimulation
of macrophages with PMA and SOD inhibitors strongly increased the activation of Akt as assessed by
immunoblot analysis of phosphorylated-Akt (p(ser473)Akt) (from ~0.6 to ~1.45 pAkt/Akt; p < 0.001
vs. CTRL).
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Figure 6. Carnosine partially reduced Akt phosphorylation levels PMA-induced in macrophages.
Representative immunoblots of phosphorylated Akt (p(ser473)Akt) and total Akt (Akt) in total protein
extracts from resting (control) macrophages and macrophages stimulated with PMA and SOD inhibitors,
in absence or presence of increasing concentrations (5, 10, or 20) of carnosine. Histograms refer to the
means ± SD of five independent experiments. The densitometric values of pAkt bands were normalized
against Akt. *** p < 0.001 vs. CTRL; # p < 0.05 vs. PMA.
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Carnosine was able to significantly attenuate this phenomenon (from ~1.45 to ~0.85 pAkt/Akt,
p < 0.05) but no differences were observed between the three concentrations tested.
In the case of Nrf2 (total and nuclear) and HO-1 protein analysis, as it was expected considering
the short duration of the stimulation time (60 min), no differences were observed among all the different
experimental conditions (Figure S2).
4. Discussion
The connections among oxidative/nitrosative stress, NADPH oxidase and NOS activity,
inflammation, and damages to biomolecules have well been characterized in various experimental
studies, using macrophages as the typical cell line actively participating to all the aforementioned
phenomena [56–59].
In the present study, using the macrophage RAW 264.7 cell line, we demonstrated that carnosine
is a compound effectively interfering with ROS generation, NADPH oxidase expression, and the
production of pro- and anti-inflammatory mediators.
We initially explored the production of O2−• induced by PMA and SOD inhibitors as well as the
antioxidant capacity of carnosine (or its methylated analogue anserine), in the RAW 264.7 macrophage
cell line, representing an established in vitro experimental model for studying oxidative stress [1,44–47].
Among the various protocols tested, we selected an acute stimulation with PMA (60 min) (Figure 1A)
giving the best combination of O2−• production and cell viability. To test carnosine activity, cells
were pre-treated for 24 h with this dipeptide since, according to our previous results, the uptake of
carnosine by RAW 264.7 macrophages increases proportionally during this time window, and it is ~3
times higher under stressing conditions [60]. In the present experiments, we found that carnosine
was able to decrease the O2−• production PMA-induced in a concentration-dependent manner, with
maximal effect observed when macrophage cells were pre-treated with 20 mM carnosine (Figure 1B).
This specific carnosine feature is likely to be of great benefit in the case of cardiovascular disease,
especially in the case of heart failure [61], hypertension and atherosclerosis [62], characterized by
excessive production and/or inadequate removal of ROS, especially O2−• [63]. Our findings are in
agreement with the previously shown carnosine antioxidant activity [38] and its ability to directly
interact with different reactive species, decreasing their bioavailability [41,64]. In order to prove that
the observed decrease in O2−• levels was in part attributable to the H atom of the secondary amine of
the imidazole ring of carnosine (easily removable as H. during ROS-mediated oxidation reactions),
macrophages were pre-treated with anserine rather than with carnosine. In line with the well-known
antioxidant properties of histidine [65,66], anserine, presenting a methyl group replacing H atom of
the secondary amine of the histidine ring, was always less effective than carnosine in reducing O2−•
levels at each concentration tested (Figure 1C). The stronger carnosine activity can in part explain
why during clinical studies investigating the potential beneficial effects of dietary anserine/carnosine
mixture supplementation on elderly people, anserine is always in excess with respect to carnosine
(from 2:1 to 3:1) [67–69].
A lot of in vitro and in vivo studies linking carnosine antioxidant activity with its protective features
are available [70,71]. In one of them, Tsai and co-workers showed the ability of this dipeptide to protect
mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) significantly attenuating
glutathione loss, retaining the activity of glutathione peroxidase and SOD enzymes, diminishing
oxidative stress, lowering pro-inflammatory cytokines and nitrite levels, and finally suppressing iNOS
activity [72].
Under the experimental conditions to stress RAW 264.7 cells, PMA caused a significant decrease
in the NAD+/NADH ratio and an increase in the NADP+/NADPH ratio (Figure 3B), demonstrating
profound changes in the cell oxido-reductive state. While the change in the NAD+/NADH ratio was of
relatively minor entity, confirming the PMA ability to increase the glycolytic rate [73], the almost 3
times increase in the NADP+/NADPH ratio strongly suggests the activation of NADPH oxidase during
PMA-mediated oxidative burst [74].
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In these experiments, only pre-treatment with 20 mM carnosine before the challenge with PMA
significantly modified the cell energy state. Contrary to previous results obtained in cultured astrocytes,
showing remarkable decrease in ATP induced by extracellular carnosine [75], we here found that the
highest dose of carnosine tested not only caused a significant increase in ATP, but also a significant
increase in GTP. According to our results, the raise in ATP might be related to increased mitochondrial
oxidative phosphorylation linked to an augmented electron transfer chain and tricarboxylic acid
activity [76,77]. Data showing a dose dependent increase in the carnosine-mediated NAD+/NADH
ratio (particularly evident when 20 mM carnosine was used) supported this hypothesis. It is also worth
underlining that carnosine dose-dependently decreased the NADP+/NADPH ratio, strongly indicating
the decrease in the activity in the main actor (NADPH oxidase) responsible for ROS production and
confirming that the improvement of cell bioenergetics has the inhibitory effects of a PMA-induced
oxidative burst [78]. This ability of carnosine to modulate energy metabolism, with specific reference
to ATP, could help reinforce the idea of its use in the treatment or prevention of diverse age-related
conditions characterized by energy dysmetabolism [79].
According with the results showed in Figure 1B and with what was aforementioned, carnosine
down-regulated the expression of both Nox1 and Nox2 enzymes, especially at the highest concentration
(20 mM) (Figure 4A,B). These results are in agreement with the ability of this dipeptide to decrease
oxidative stress-related enzymes, protecting microglial cells challenged with the oligomeric form of
amyloid-β peptide [43]. A completely different scenario was observed when we investigated the effect
of carnosine on pro- and anti-inflammatory cytokine genes expression in stimulated macrophages. In
fact, on one hand the pre-treatment with carnosine was able to significantly (p < 0.001) down-regulate
the expression of TNF-α and IL-6 mRNAs (Figure 5A,B); on the other hand, carnosine up-regulated
the expression of IL-4 and IL-10 mRNAs (Figure 5E,F), also rescuing the TGF-β1 expression level
to the values detected in resting cells, which was significantly higher than that of PMA alone
(Figure 5D). These results point to an important role of carnosine in counteracting inflammatory
phenomena promoting the transition in macrophages from a pro-inflammatory to an anti-inflammatory
phenotype [80]. This “macrophage transition” plays a fundamental role in many diseases; in fact, the
ratio of pro-inflammatory/anti-inflammatory macrophages, highly regulated in normal tissues, increases
during diseases [80,81]. Therefore, the ability of carnosine to push towards an anti-inflammatory
macrophage phenotype could, in part, make the difference between health and a pathological state.
During the last decade, the therapeutic potential of TGF-β1 in diseases characterized by oxidative
stress and inflammation such as AD has emerged [82]. Carnosine in our experimental model induced
a robust TGF-β1 overexpression. It has been shown that TGF-β1 administration protects rats against
neuroinflammation and neurodegeneration Aβ-induced [82–85], while TGF-β1 knockout mice die
from multifocal inflammation and autoimmune disorders in internal organs [86,87], highlighting
the protective role of this multifunctional cytokine in protecting against inflammatory events. The
ability of carnosine in counteracting the activation of Akt, enhanced in different cell types under stress
conditions [48,88] and connected to the production of pro-inflammatory cytokines in macrophages [48],
confirmed previous results obtained under different experimental conditions [48,89–91].
Our study produced robust evidences that carnosine effectively inhibits pro-oxidant and
pro-inflammatory conditions in macrophages. Results demonstrated that the effects of carnosine are not
only connected to the modulation of canonical pathways and activities causing oxidative/nitrosative
stress and inflammation, but also that they are strictly linked to the capacity of this molecule
to interact positively with the cell bioenergetics. Since the number of pathological conditions
causing mitochondrial dysfunction and energy deficit are continuously increasing [92], it appears
that the data showing the unexpected beneficial effects of carnosine on energy metabolism, related to
improved mitochondrial oxidative phosphorylation and electron transport chain, looks particularly
relevant in light of the potential application of this dipeptide in the treatment of pathologies such as
neurodegenerative disorders.
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5. Conclusions
In the present study we provided evidence that carnosine is able to reduce oxidative stress and
inflammation, simultaneously restoring the parameters of cellular energy metabolism in activated
macrophage cells. We reported for the first time that carnosine reduces PMA-induced oxidative stress
in RAW 264.7 macrophage cells by decreasing the expression of Nox1 and Nox2 genes as well as the
intracellular superoxide anion levels. In our experimental model, carnosine was also able to attenuate
the PMA-induced Akt phosphorylation, down-regulate the expression of TNF-α and IL-6 mRNAs,
simultaneously up-regulating the expression of the anti-inflammatory mediators IL-4 and IL-10, and
rescuing TGF-β1 expression levels. Further, when used at the highest concentration, the antioxidant
and anti-inflammatory effects of carnosine were accompanied by a generalized amelioration of the
macrophage energy state, evaluated through the increase both in the total nucleoside triphosphate
concentrations and the sum of the pool of intracellular nicotinic coenzymes. Finally, carnosine decreases
the NADP+/NADPH ratio in a concentration dependent manner, indicating a strong inhibitory effect
of this molecule towards the main source of ROS in this cell line.
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